Verisian builds deep tech and AI solutions that automate the validation, documentation, and regulatory compliance processes for clinical trial submissions. The company's cloud-native platform automates validation of SDTM and ADaM analyses, generates submission documentation, and ensures compliance with FDA, PMDA, and NMPA requirements across the United States, Japan, and China.
The platform replaces traditional double programming approaches with AI-powered validation and full study traceability. It integrates with existing infrastructure through simple file transfer, removing technical barriers to adoption. Verisian claims that organizations can establish leadership in clinical AI within days rather than months, while reducing time-to-market and improving the quality and transparency of clinical submissions.
The company serves pharmaceutical companies, medical device manufacturers, clinical research organisations, and public health authorities. Its focus on automation and transparency reflects a commitment to accelerating the pace at which medical therapies reach patients safely.
